This week GSK unveiled its crown jewels: a full pipeline of compounds in research and development, the result of a £2.6 billion ($4.5 billion), 16,000-researcher-strong effort.
This finding suggested that these compounds can serve as new lead compounds in research on antibacterial chemotherapy.
The results indicated that compound 23e and 23i may serve as novel lead compounds in research on more effective anticancer agents.
Its excellent profiles in vitro and effectivity in vivo highlight this structurally distinct compound as a potential lead compound in the research of innovative multifunctional drugs for AD.
A series of novel derivatives of N-cinnamoyl-l-aspartic acid were designed, synthesized, and assayed for their inhibitory activities against aminopeptidase N. The preliminary biological assay showed that compound 8c has the most potent inhibitory activity against APN with an IC50 of 11.1 ± 0.9 μM, this could be used as the lead compound in future research on anticancer agents.
That could greatly expand the number of tracer compounds used in research, he says, which in turn may lead to benefits in treating a wide variety of diseases.
In our previous work, we studied the catalysis of aliphatic ester polymerization by low toxicity iron compounds, instead of the stannum compounds used commonly in research or/and industry [ 15].
Given the above results, this kind of compounds could serve as new lead compounds in the research of antimicrobial chemotherapy.
In combination with the activity test of the three compounds in this research group, the three indexes were comprehensively evaluated.
As a result, scaffolds containing five-membered heterocycles have received much attention for the rapid generation of potential lead compounds in pharmaceutical research [4 11].
Application of these compounds in basic research has substantially contributed to the elucidation of calcineurin-dependent signalling processes [ 40, 41].
